Copertina

Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Jessica Ailani, Pranav Gandhi, Anjana Lalla, Rashmi Halker Singh, Peter McAllister, Jonathan H. Smith, Brett Dabruzzo, Natty Chalermpalanupap, Kari Kelton, Stephanie J. Nahas
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Headache: The Journal of Head and Face Pain
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete‐choice experiment
di: Richard B. Lipton, et al.
Pubblicazione: (2025)

Characterizing gaps in the preventive pharmacologic treatment of migraine: Multi‐country results from the CaMEO‐I study
di: Dawn C. Buse, et al.
Pubblicazione: (2024)

Long‐term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication‐overuse headache
di: Andrew Blumenfeld, et al.
Pubblicazione: (2024)

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine
di: David Kudrow, et al.
Pubblicazione: (2025)

Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial
di: Koichi Ikeda, et al.
Pubblicazione: (2025)

Integrating gepants into clinical practice for the acute treatment of migraine
di: Richard B. Lipton, et al.
Pubblicazione: (2026)

Migraine in women
di: Arathi Nandyala, et al.
Pubblicazione: (2024)

Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States
di: Noah Rosen, et al.
Pubblicazione: (2025)

Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo‐controlled clinical trials
di: Larry Charleston, et al.
Pubblicazione: (2026)

Three years of remote electrical neuromodulation (REN) acute treatment for migraine shows consistent effectiveness and no tachyphylaxis phenomenon
di: Stephanie J. Nahas, et al.
Pubblicazione: (2025)

Comprehensive assessment of erenumab efficacy in participants with high‐frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study
di: Gabriel Paiva da Silva Lima, et al.
Pubblicazione: (2025)

Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open‐label ASCEND acute migraine study
di: Jessica Ailani, et al.
Pubblicazione: (2025)

Unmet treatment needs in migraine: Results of the OVERCOME (US) study
di: Susan Hutchinson, et al.
Pubblicazione: (2026)

Microneedles for the treatment of migraine and orofacial pain: A narrative review
di: Baicheng Cao, et al.
Pubblicazione: (2026)

Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
di: Shuu‐Jiun Wang, et al.
Pubblicazione: (2024)

Delayed urticaria during treatment with anti‐ CGRP monoclonal antibodies in migraine
di: Christoph T. Berger, et al.
Pubblicazione: (2026)

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
di: Chia‐Chun Chiang, et al.
Pubblicazione: (2024)

Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment
di: Andrea M. Kuczynski, et al.
Pubblicazione: (2025)

A phase 1, multicenter, open‐label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine
di: Chay Ngee Lim, et al.
Pubblicazione: (2025)

Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME ( US ) study
di: Jessica Ailani, et al.
Pubblicazione: (2026)

Navigating the patient journey in migraine prevention: An American Migraine Foundation position paper
di: Lawrence C. Newman, et al.
Pubblicazione: (2025)

Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing
di: Richard B. Lipton, et al.
Pubblicazione: (2025)

Habitual caffeinated beverage consumption and headaches among adults with episodic migraine: A prospective cohort study
di: Maggie R. Mittleman, et al.
Pubblicazione: (2024)

Patient preferences for preventive migraine treatments among Canadian adults: A discrete choice experiment
di: Joanna K. Bougie, et al.
Pubblicazione: (2024)

Do patients with migraine and obesity receive different treatments? Insights from real‐world data
di: Keshet Pardo, et al.
Pubblicazione: (2025)

Novel optimization of multi‐mechanistic approaches for the acute treatment of a migraine attack: A review
di: Stephen Silberstein, et al.
Pubblicazione: (2026)

The impact of the migraine treatment onabotulinumtoxinA on inflammatory and pain responses: Insights from an animal model
di: Philip Victor Reducha, et al.
Pubblicazione: (2024)

Identifying cognitive‐affective mechanisms underlying disability in episodic migraine: Using the fear avoidance model to examine interactions
di: Janosch Fox, et al.
Pubblicazione: (2025)

Randomized controlled trial of intravenous dexamethasone to prevent relapse in the treatment of migraine in a pediatric emergency department
di: Geneviève Tourigny‐Ruel, et al.
Pubblicazione: (2026)

Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial
di: Muneto Tatsumoto, et al.
Pubblicazione: (2024)

Routine migraine screening as a standard of care for Women's health: A position statement from the American Headache Society
di: Todd J. Schwedt, et al.
Pubblicazione: (2025)

Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study
di: David W. Dodick, et al.
Pubblicazione: (2025)

Correction to “Smartphone‐delivered progressive muscle relaxation for the treatment of migraine in primary care: A randomized controlled trial”
Pubblicazione: (2025)

Changes in brainstem habituation during onabotulinumtoxinA treatment in chronic migraine: A prospective case–control study
di: Gerlinde Freimark, et al.
Pubblicazione: (2025)

Long‐term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial
di: Anna Gryglas‐Dworak, et al.
Pubblicazione: (2024)

2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies
di: Jennifer Robblee, et al.
Pubblicazione: (2025)

The 2023 protocol for update to acute treatment of adults with migraine in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies
di: Jennifer Robblee, et al.
Pubblicazione: (2024)

Safety analysis of gepants for migraine treatment: A pharmacovigilance study using the FDA Adverse Event Reporting System ( FAERS ) database
di: Hui Chen, et al.
Pubblicazione: (2026)

Partial rebreathing is not effective for early treatment of migraine with aura attacks: Results of a double‐blind, randomized, controlled trial ( PAREMA1 )
di: Charly Gaul, et al.
Pubblicazione: (2025)

Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders—A retrospective tolerability and safety study
di: Christopher C. Anderson, et al.
Pubblicazione: (2024)